For Research Use Only. Not for Clinical Use.

In recent years, the extension of drug half-life has gradually become a hot spot. Creative Biolabs is a leading service provider in the extension of drug half-life for basic research and clinical applications. We provide high-quality half-life extension methods applicable for a variety of research purposes.

Introduction of Chronic Plaque Psoriasis

Fig.1 Silvery scale of psoriasis.

Psoriasis is a T-cell-mediated autoimmune, chronic inflammatory disease that appears in the skin. Among the various types of psoriasis, chronic plaque psoriasis is the most common. The distribution of chronic plaque psoriasis in the body may be local or extensive. The typical feature of chronic plaque psoriasis is red patches of thickened skin covered in silver scales. Although any area of the body may be affected, the main areas are the elbows, knees, lower back, and scalp.

Causes of Chronic Plaque Psoriasis

Psoriasis is recognized as an immune-mediated disorder, with tumor necrosis factor alpha (TNFα), dendritic cells, and T-cells all inducing the development of psoriasis. These facts provide evidence for the genetic basis of the disease. However, the way that psoriasis develops appears to be influenced by environmental factors, such as infections, certain drugs, endocrine factors, alcohol, smoking, and stress.

Treatments for Chronic Plaque Psoriasis

Since chronic plaque psoriasis is a long-term disease, effective treatment of psoriasis is very important. Topical treatments applied to the skin are usually tried first. These include vitamin D analogs, topical corticosteroids, steroids, and vitamin A products. Among these treatments, vitamin D derivatives and steroids are the most frequently used therapy. Patients not responding to topical therapy can be treated by light therapy; traditional systemic therapy; or systemic treatment with immunomodulatory drugs.

Application of Half-life Extended Drug in Chronic Plaque Psoriasis

The Fc-fusion proteins have been successfully applied in a variety of diseases, including psoriasis. Advances of these therapeutic proteins may improve patient adherence by helping extend the drug half-life with longer dosing intervals. To date, there are many Fc-fusion protein therapeutics. The first successful example is a human TNF receptor p75 Fc fusion protein which employs a soluble receptor-Fc fusion protein as a therapeutic drug. The Fc fragment extends the half-life of the drug, resulting in a promising effect in psoriasis. Moreover, another novel biologic agent has been developed for psoriasis. The novel biologic agent is a human recombinant dimeric fusion protein that contains the first extracellular domain of Leukocyte Functioning Antigen-3 (LFA-3) and the Fc portion of human IgG1. The drug is well-tolerated and plays an important role in treating psoriasis in different ways. It has been approved for treating psoriasis. In addition, there has been an increased interest in the novel drug and the drug may be formally explored in the future.

We have successfully provided many services on drug half-life extension according to customer needs. If you are interested in our services, please feel free to contact us.